— Know what they know.
Not Investment Advice
Also trades as: LMDXW (NASDAQ) · $vol 0M

LMDX NASDAQ

LumiraDx Limited
1W: +15.1% 1M: +60.0% 3M: -83.2% 1Y: -98.7%
$0.02
Last traded 2025-06-17 — delisted
NASDAQ · Healthcare · Medical - Diagnostics & Research · $5.1M mcap

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$254M -39.6% ▼
3Y CAGR: +122.4%
Gross Profit
-$35M -123.3% ▼
Operating Income
-$321M -1705.4% ▼
Net Income
-$449M -345.8% ▼
EPS (Diluted)
$-1.59 -156.5% ▼
EBITDA
-$274M -698.1% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2019FY2020FY2021FY2022
Revenue$23M$139M$421M$254M
YoY Growth+0.0%+501.3%+202.9%-39.6%
Cost of Revenue$14M$86M$270M$290M
Gross Profit$9M$53M$152M-$35M
Gross Margin38.1%38.0%36.0%-13.9%
R&D Expenses$87M$108M$130M$142M
SG&A Expenses$37M$46M$131M$145M
Operating Expenses$124M$154M$297M$287M
Operating Income-$115M-$101M$20M-$321M
Operating Margin-497.0%-72.4%4.8%-126.3%
Interest Expense$17M$32M$118M$135M
Income Before Tax-$143M-$251M-$98M-$443M
Tax Expense-$10M-$10M$3M$4M
Net Income-$133M-$241M-$101M-$449M
Net Margin-575.2%-173.2%-23.9%-176.5%
EPS (Diluted)$-0.53$-0.95$-0.62$-1.59
EBITDA-$127M-$118M$46M-$274M
Shares Outstanding253M253M163M282M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms